Operating executive with experience scaling technology and healthcare businesses, known for go-to-market strategy, commercial operations, and growth-stage operational rigor. Chris Lein brings senior leadership across product, sales and corporate development roles at venture-backed companies and PE portfolio firms, advising on revenue scaling, M&A readiness and KPI-driven transformation. Market-facing profile includes board advisory, interim CRO/CBO assignments, and collaboration with growth equity investors on post-investment operational plans.
Operating executive with experience scaling technology and healthcare businesses, known for go-to-market strategy, commercial operations, and growth-stage operational rigor. Chris Lein brings senior leadership across product, sales and corporate development roles at venture-backed companies and PE portfolio firms, advising on revenue scaling, M&A readiness and KPI-driven transformation. Market-facing profile includes board advisory, interim CRO/CBO assignments, and collaboration with growth equity investors on post-investment operational plans.
Advises growth-oriented investments with a hands-on, operator-led approach focused on commercial value creation in technology and healthcare. Prioritizes capital deployment toward scalable go-to-market, sales enablement and product-led revenue expansion, using KPI-driven roadmaps and short- to mid-term milestones to de-risk execution. Emphasizes M&A readiness and bolt-on consolidation as exit-enhancing levers, aligns management incentives to revenue/ARR and margin inflection, and favors disciplined stage-appropriate capital with operational playbooks to accelerate portfolio growth.
Advises growth-oriented investments with a hands-on, operator-led approach focused on commercial value creation in technology and healthcare. Prioritizes capital deployment toward scalable go-to-market, sales enablement and product-led revenue expansion, using KPI-driven roadmaps and short- to mid-term milestones to de-risk execution. Emphasizes M&A readiness and bolt-on consolidation as exit-enhancing levers, aligns management incentives to revenue/ARR and margin inflection, and favors disciplined stage-appropriate capital with operational playbooks to accelerate portfolio growth.
| Trades 570 | Longs Won 437/570 76% | Profit Factor 9.16 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $138,276.96 |
| Average Win $51,726.41 | Best Trade (Aug 31) $1.61M | Sharpe Ratio -9.27 |
| Average Loss -$18,546.79 | Worst Trade (Aug 19) -$1.34M | Z-Score 9.33 (100%) |
| Commissions $0 | Avg. Trade Length 11m 1w | Expectancy $35,329.33 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 5,682 | 5,114 | 4,545 | 3,977 | 3,409 | 2,841 | 2,273 | 1,705 | 1,136 | 568 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 24,584 | $6.16M | $7.59M | - | $1.43M | 23.27% | -7.354% |
ADI Analog Devices, Inc. | 544 | $216,060 | $199,871.04 | - | -$16,188.96 | -7.49% | +0.202% |
ADP Automatic Data Processing Inc. | 1,061 | $310,586.17 | $282,714.05 | - | -$27,872.12 | -8.97% | +0.982% |
AGOX Adaptive Alpha Opportunities ETF | 221,209 | $6.23M | $7.38M | - | $1.15M | 18.43% | +0.907% |
ALL Allstate Corporation | 3,307 | $786,780 | $873,312.52 | - | $86,532.52 | 11% | -0.49% |
AMAX Adaptive Hedged Multi-Asset Income ETF | 892,491 | $6.96M | $6.61M | - | -$350,496.85 | -5.03% | +0.135% |
AMD Advanced Micro Devices, Inc. | 1,763 | $285,236.02 | $839,452.43 | - | $554,216.41 | 194.3% | -1.904% |
AMZN Amazon.com Inc | 7,605 | $1.66M | $2.07M | - | $403,020.37 | 24.24% | +15.321% |
ARTY iShares Future AI & Tech ETF | 7,010 | $266,725.67 | $467,216.5 | - | $200,490.83 | 75.17% | +0.604% |
AVGO Broadcom Inc. | 1,165 | $272,447.47 | $453,511.2 | - | $181,063.73 | 66.46% | +0.371% |
AXP American Express Company | 597 | $201,935 | $200,741.25 | - | -$1,193.75 | -0.59% | -0.376% |
BP BP p.l.c. Sponsored ADR | 16,876 | $501,299.2 | $763,132.72 | - | $261,833.52 | 52.23% | +2.261% |
BRK-B Berkshire Hathaway Inc. | 6,658 | $3.02M | $3.41M | - | $388,060.37 | 12.86% | +0.365% |
BYLD iShares Yield Optimized Bond ETF | 50,093 | $1.11M | $1.12M | - | $6,254.31 | 0.56% | -0.179% |
CAT Caterpillar Inc. | 665 | $241,235.26 | $541,848.65 | - | $300,613.39 | 124.61% | +0.701% |
CLSE Convergence Long/Short Equity Fund | 5,940 | $202,762 | $201,900.6 | - | -$861.4 | -0.42% | +0.236% |
CSX CSX Corporation | 20,520 | $662,176.95 | $1.03M | - | $372,031.05 | 56.18% | +0.418% |
CVX Chevron Corporation | 2,632 | $386,847.75 | $518,056.56 | - | $131,208.81 | 33.92% | +2.35% |
DAL Delta Air Lines, Inc. | 4,384 | $245,763.68 | $383,336.96 | - | $137,573.28 | 55.98% | -1.298% |
DBE Invesco DB Energy Fund | 16,967 | $316,680.52 | $530,049.08 | - | $213,368.56 | 67.38% | +1.133% |